Allogene Therapeutics
Debbie Messemer has more than 30 years of experience providing financial expertise to public and private companies and was the Managing Partner of KPMG’s Bay Area and Northwest region until her recent retirement. Debbie, a certified public accountant (CPA), joined KPMG LLP, the U.S. member firm of KPMG International, in 1982 and was admitted into partnership in 1995. As Managing Partner for the Bay Area and Northwest region, she was responsible for leading over 3,000 team members in 10 offices across all functions, including audit, tax and advisory. Debbie spent the majority of her career in KPMG’s audit practice as an audit engagement partner serving public and private clients in a variety of industry sectors. In addition to audit signing responsibilities, she has significant experience in SEC filings, due diligence, initial public offerings, mergers and acquisitions, and internal controls over financial reporting. Debbie is a member of the National Association of Corporate Directors (NACD) and of the San Francisco Chapter of Women Corporate Directors (WCD). She has served extensively on non-profit and advisory boards including the Bay Area Council, the San Francisco Committee on Jobs, the California Chamber of Commerce, the San Francisco Chamber of Commerce, the UC Berkeley Fisher Center Policy Advisory Board, San Francisco Ballet, and Posse. Debbie received a bachelor’s degree in accounting from the University of Texas at Arlington.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.